Jcog1104
http://www.jcog.jp/document/1104.pdf Web(JCOG1104) trial, a Phase III study, to evaluate the overall efficacy of four courses of S‐1 adjuvant chemotherapy as compared to eight courses of the same regimen in patients who were diagnosed with pStage II after surgery. At the planned first interim, four courses of S‐1 were inferior to eight courses of S‐1 in terms of RFS, and the
Jcog1104
Did you know?
Web22 gen 2024 · Background: The phase III trial (JCOG1104), comparing between 4- (6 months) and 8-course (1 year) of S-1 as the adjuvant chemotherapy for pathological … Web7 ott 2024 · Recently, JCOG1104 trail further revealed the overall survival of stage II gastric cancer patients with eight course adjuvant S1 was better than those with four courses, but T1N2-3 and T3N0 were excluded . However, most patients in the INT-0116 study underwent D0 or D1 gastrectomy (a total of 90%).
Web14 ott 2024 · For pStage II gastric cancer, the ACTS-GC trial revealed satisfactory survival outcomes (84.2% of 5-year OS); thus, the possible feasibility of shorter S-1 duration was evaluated in JCOG1104. The study was terminated at the first interim analysis with HR for the 6-month group versus the 12-month group being 2.52 (95% CI, 1.11–5.77), which … Web28 apr 2024 · Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.
Web29 set 2024 · 4 Courses and 8 Courses of S-1 Adjuvant Chemotherapy for Pathological Stage II Gastric Cancer JCOG1104 (OPAS-1): A Phase 3, Open-Label, Non-Inferiority, …
WebBACKGROUND: Postoperative adjuvant chemotherapy with S-1 for 1 year (corresponding to eight courses) is standard care for stage II gastric cancer. Whether the duration of S-1 could be shortened to 6 months (corresponding to four courses) without worsening survival is unclear. The aim of this study was to investigate the non-inferiority of four courses of S-1 …
Web2 apr 2024 · In another phase III trial named the optimal period of adjuvant S-1 chemotherapy for patients with pStage II gastric cancer who underwent D2 gastrectomy (JCOG1104), the non-inferiority of the primary end point of the 3-year disease-free survival in patients who had been administered eight courses of adjuvant S-1 monotherapy … cheap family plans no contractWeb5 mag 2024 · JCOG1104 was conducted as to demonstrate the non-inferiority of four courses of S-1 to standard eight courses of S-1, because the efficacy of S-1 appears to … cvs pharmacy 2410 charleston hwyWeb23 gen 2024 · Next Article Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Summary. Background. Laparoscopic pancreatoduodenectomy may improve postoperative recovery compared with open pancreatoduodenectomy. cvs pharmacy 2313 w university dr mckinney txWeb過去の臨床試験. HOME ＞ 臨床試験報告 ＞ 過去の臨床試験. 【JCOG9501】. 大動脈周囲リンパ節郭清の臨床的意義に関する研究. 【JCOG9502】. 食道浸潤胃がんの外科治療に関する比較臨床試験. 【JCOG0001】. 高度リンパ節転移を伴う進行胃がんに対する術 … cheap family plan cell phone serviceWeb18 gen 2024 · Log in. Sign up cheap family plans with unlimited textingWebJCOG1104：「病理学的Stage II 胃癌に対するS-1術後補助化学療法の期間短縮の意義を検討するランダム化 比較第III相試験」 研究代表者 氏名 寺島雅典 所属 静岡県立静岡がん … cheap family photography near meWebJCOG 1104 ver1.4 2/ 84 0.概要 0.1. シェーマ. 0.2. 目的. 胃癌. D1 ＋/D2 術後の病理学的Stage II（病理学的T1N2-3 および病理学的T3N0を除く）の患者を対象と cvs pharmacy 23 mile and romeo plank